DraftUnitedHealthcarePolicy CS009NJ.S

Spinal Fusion and Bone Healing Enhancement Products (for New Jersey Only)

This New Jersey–specific medical policy governs coverage and medical necessity determinations for spinal fusion grafts, biologics, and bone‑healing enhancement products used in spinal fusion procedures for UnitedHealthcare members in New Jersey.

Policy Summary

PayerUnitedHealthcare

PolicySpinal Fusion and Bone Healing Enhancement Products (for New Jersey Only)

Policy CodePolicy CS009NJ.S

Change TypeAdditions and clarifications to coverage stance and documentationdefinitions added

Effective DateDec 1, 2025

Next Review Date

Key ActionEnsure medical records include history, physical exam, and pertinent diagnostic test results (legible and available) to support medical necessity and prior authorization when required.

SourceLink

POLICY UPDATE CHANGES

Added language to clarify Ceramic-Based Products (e.g., beta tricalcium phosphate, calcium phosphate, calcium sulfate) used alone or in combination with other grafts and/or graft components, including Bone Marrow Aspirate (BMA), are unproven and not medically necessary.

Added medical records documentation language indicating that benefit coverage is determined by federal, state, or contractual requirements and that medical records may be required to assess clinical criteria for coverage.

Added definitions for osseointegration, osteoconduction, and osteoinduction and updated definitions for allograft, autograft, and bone marrow aspiration.

Updated Clinical Evidence, FDA, and References sections to reflect the most current information.

Removed reference links to the Medical Policies: Interspinous Fusion and Decompression Devices (for New Jersey Only) and Spinal Fusion and Decompression (for New Jersey Only).

L2–S1 single-levelSpecific covered indication for rhBMP-2 (InFUSE)

Ceramic products, cell-based allografts

Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.

Products considered not medically necessary

Multiple assessmentsEvidence reviews summarized

New Jersey onlyGeographic scope

20+ trialsRCTs summarized

Small samplesEvidence limitations noted

Coverage Criteria and Evidence Summary

Not Medically Necessary — Ceramic-Based Products

The following are unproven and not medically necessary for the enhancement of spinal fusion and bone healing due to insufficient evidence of efficacy and/or safety. This criteria group restates policy stance on ceramic-based products and related rationale.

Ceramic-Based Products — Not Medically Necessary when used alone or in combination with other grafts and/or graft components (including Bone Marrow Aspirate [BMA]). Examples include, but are not limited to: beta tricalcium phosphate (b-TCP), calcium phosphate, calcium sulfate, biphasic calcium phosphate preparations, and other ceramic-based synthetics.

Rationale: There is insufficient high-quality, consistent evidence to determine the safety and efficacy of ceramic-based products for spinal fusion. Clinical studies vary widely in product composition, manufacturing, porosity, study design, and reported outcomes. While some randomized, intra-patient, noninferiority trials (e.g., MagnetOs Granules, AttraX Putty) have reported noninferiority or favorable fusion rates in specific operative contexts, overall evidence is mixed and limited by methodological issues, heterogeneous procedures, small sample sizes, sponsorship bias, and limited patient-reported outcome attribution. Systematic reviews and ECRI assessments conclude that superiority to iliac crest bone graft (ICBG) or consistent equivalence across indications cannot be established.

Scope of exclusion (operational note): Ceramic-based products are considered not medically necessary whether used as stand-alone bone graft substitutes or when combined with other grafts or adjuncts such as Bone Marrow Aspirate (BMA). This includes ceramic granules, putties, spacers, and cages composed of ceramic materials when intended to enhance spinal fusion.

Clinical considerations (operational note): If a treating clinician believes use of a ceramic-based product is medically necessary for an individual patient, documentation must demonstrate why standard, proven options (e.g., autograft, DBM, or other covered allograft products) are not suitable and provide supporting clinical evidence. Documentation may be requested for medical review but does not guarantee coverage.

Evidence summary (supporting points):

o Multiple evidence assessments (ECRI 2022, 2024) and systematic reviews report insufficient, low- to very-low-quality data to establish consistent benefit of ceramic substitutes versus autograft or other graft materials across fusion procedures.

o Individual trials have methodological limitations (intra-patient designs, limited PROM attribution, short follow-up, sponsorship) that limit generalizability and preclude broad coverage determination.

o Given heterogeneity of ceramic products and mixed outcomes across cervical, lumbar, interbody, and posterolateral fusion studies, the policy treats ceramic-based products collectively as unproven for routine coverage.

Related policy action (operational note): Ceramic-based products listed above are classified as not medically necessary for enhancement of spinal fusion and bone healing and are excluded from routine coverage under this policy.

Coding and Regulatory References

Applicable Codes (reference list)CPT

0814T	Percutaneous injection of calcium-based biodegradable osteoconductive material, proximal femur, including imaging guidance, unilateral
20930	Allograft, morselized, or placement of osteopromotive material, for spine surgery only (List separately in addition to code for primary procedure)
20931	Allograft, structural, for spine surgery only (List separately in addition to code for primary procedure)
20939	Bone marrow aspiration for bone grafting, spine surgery only, through separate skin or fascial incision (List separately in addition to code for primary procedure)
22899	Unlisted procedure, spine

FDA device documents referencedmixed

K210155	FDA 510(k) premarket approval for Duo™ Expandable Interbody Fusion System (document id referenced)
K014200	FDA 510(k) premarket approval for OptiMesh® Expandable Interbody Fusion System (document id referenced)
DEN200010	FDA De Novo classification ID for OptiMesh® expanded indications
320591	FDA PMA database ID referenced for a device (document id referenced)
375525	FDA Humanitarian Device Exemption ID referenced for InFUSE/MASTERGRAFT

Provider Actions, Prior Authorization, and Documentation

Documentation Required

Code reference and supporting documentation requirement

The following codes are provided for reference only. Listing a code does not guarantee coverage or payment; medical records must support medical necessity for billed services.

Applicable CPT/HCPCS/other procedure and diagnosis codes are examples; verify contractual and state-specific coverage.
Codes labeled with an asterisk (*) may not be covered by New Jersey Medicaid.

Prior Authorization

Prior authorization and safety risk — rhBMP-2 cervical (off‑label) use

Off-label use of rhBMP-2 (InFUSE) for cervical fusion has been associated with life‑threatening adverse events (e.g., airway or neurologic compression). Prior authorization may be required and such requests will be subject to focused review of risks, indications, and dosing; off‑label cervical use may be denied when safety concerns are not adequately mitigated.

Clinical Background

Historically, autologous iliac crest bone graft (ICBG) has been the gold standard for spinal fusion because it provides combined osteoconductive, osteoinductive, and osteogenic properties. Although ICBG is effective, donor‑site morbidity has encouraged development of adjuncts and substitutes (for example, BMA, rhBMP‑2, DBM), but many newer products remain under investigation due to limited comparative evidence.

Definitions

Allograft — definition entry

TermAllograft

DefinitionThe transplant of an organ or tissue from one individual to another of the same species with a different genotype; also known as an allogeneic graft or homograft.

Contextual useUsed as structural (cortical/corticocancellous) or nonstructural graft material for spinal fusion, often as an alternative to autograft.

Autograft — definition entry

TermAutograft

DefinitionTissue grafted into a new position in the body of the same individual.

Contextual use

Revision History and Policy Changes

2025-12-01policy_revisionLatest

Added coverage rationale clarifying that Ceramic-Based Products (e.g., beta tricalcium phosphate, calcium phosphate, calcium sulfate) used alone or in combination with other grafts and graft components, including Bone Marrow Aspirate (BMA), are unproven and not medically necessary; removed reference links to two New Jersey–specific related medical policies.

2025-12-01policy_revision

Added medical records documentation language specifying that benefit coverage is determined by federal, state, or contractual requirements; medical records may be required to assess clinical criteria and must be legible and made available upon request.

Policy Summary

PayerUnitedHealthcare

PolicySpinal Fusion and Bone Healing Enhancement Products (for New Jersey Only)

Policy CodePolicy CS009NJ.S

Change TypeAdditions and clarifications to coverage stance and documentationdefinitions added

Effective DateDec 1, 2025

Next Review Date

Key ActionEnsure medical records include history, physical exam, and pertinent diagnostic test results (legible and available) to support medical necessity and prior authorization when required.

SourceLink

On This Page

ECRI and systematic reviews report higher adverse event rates for cervical rhBMP-2 use.

FDA public health notifications warn of life‑threatening complications with off‑label cervical use.

Prior Authorization

Prior authorization — device indications and FDA documentation

When requesting coverage for implants, devices, or systems, include documentation of device‑specific FDA approvals/clearances or exemptions. Prior authorization may be required when device indications differ from FDA labeling or when product is used off‑label.

Provide FDA 510(k), PMA, De Novo, or HDE reference (including URL) when available.
Examples: InFUSE/LT‑CAGE 510(k)/PMA references; OptiMesh and Duo expandable system 510(k)/De Novo references.

Denial Risk

Documentation-related denial risk

Insufficient, illegible, or missing medical records that fail to demonstrate history, physical exam findings, diagnostic test results, imaging, and rationale for the requested graft/device may result in denial of the request.

Medical record must be legible and available upon request.
Include relevant history, exam, prior treatments, imaging reports, and justification linking clinical findings to the requested service.

Prior Authorization

Prior authorization and evidence insufficiency — ceramic-based products and bioactive glass

Ceramic-based products and bioactive glass substitutes have limited and mixed evidence; coverage decisions may require prior authorization and case-by-case review to establish medical necessity.

Evidence is heterogeneous; superiority to iliac crest bone graft (ICBG) is not established.
Payers may require demonstration that established graft materials were considered prior to use of ceramics or bioactive glass.

Note

Evidence insufficiency — expandable interbody fusion systems

Expandable interbody fusion systems currently lack high-quality RCT evidence demonstrating improved patient‑oriented outcomes; coverage may be limited or require additional documentation and review.

ECRI assessment found very low‑quality data; few prospective RCTs with long‑term outcomes.
Requests for expandable systems may trigger medical necessity review and require outcomes data reporting.

Documentation Required

Imaging and outcomes documentation requirements

Imaging and outcomes documentation are required to support fusion claims and assess treatment success. Include radiographic fusion assessments (CT thin‑slice when applicable) and patient‑reported outcomes where available.

Fusion assessment should include CT thin‑slice imaging and report timepoints (commonly 1–2 years) when indicated.
Where applicable, include validated PROMs (e.g., ODI, VAS) and post‑operative clinical notes documenting progress.

Note

When intra‑patient controlled trials are used — radiographic follow‑up expectations

When intra‑patient controlled trials are used as evidence, typical radiographic follow‑up includes CT assessment at approximately 1 year and additional CT (or CT thin‑slice) at 1–2 years if fusion is not confirmed at earlier timepoints. Note limitations: intra‑patient designs may not attribute PROMs or AEs to one graft type uniquely.

CT‑based fusion scoring at 1 year is commonly used; additional CT at 2 years may be performed if fusion uncertain.
Document limitations of intra‑patient comparisons in supporting clinical outcome attribution.

Documentation Required

Comprehensive medical records requirements

Medical records must fully support the medical necessity for requested services, including relevant medical history, physical examination, prior conservative treatments, diagnostic test results, imaging reports, operative notes, device/graft product name and manufacturer, and rationale for choice of graft/device.

Records should include device/product FDA documentation or clearance references when applicable.
Include documentation that established graft materials (e.g., ICBG, allograft) were considered and reasons for selecting substitutes or extenders.

Step Therapy

Step approach and consideration of established graft materials

Step considerations among osteobiologics: given limited comparative evidence, consider established graft materials (ICBG/autograft, allograft) before newer substitutes or extenders; rhBMP-2 may compare favorably to autograft for certain FDA‑approved lumbar indications but off‑label uses require justification.

Autograft/ICBG remains the gold standard; extenders and substitutes are adjuncts.
Document prior consideration of autograft/allograft and specific clinical factors (e.g., inability to harvest, revision surgery) when requesting biologics or substitutes.

Considered the historical gold standard (e.g., iliac crest bone graft) for spinal fusion due to combined osteoconductive, osteoinductive, and osteogenic properties.

InFUSE 12 Bone Graft (rhBMP-2) — definition and indications

DefinitionA bone graft product that contains recombinant human bone morphogenetic protein-2 (rhBMP-2) applied on an absorbable collagen sponge to stimulate bone formation.

Demineralized Bone Matrix (DBM) — definition and carrier notes

TermDemineralized Bone Matrix (DBM)

DefinitionA type of allograft produced by dissolving the mineralized portion of bone and leaving the collagen matrix and retained growth factors; the collagen matrix provides weak osteoconductive capacity while retained growth factors are osteoinductive.

Carrier requirementDBM must be combined with a carrier that serves as a more potent osteoconductive scaffold.

rhBMP-2 (Infuse) — definition and indication detail

TermrhBMP-2 (Infuse)

DefinitionRecombinant human bone morphogenetic protein-2 delivered on an absorbable collagen sponge to promote vertebral fusion by stimulating host osteogenesis.

Allograft-based and cell-based products — examples and definition

TermAllograft-based and cell-based products

DefinitionGrafts derived from donated human bone and, in some products, containing preserved bone-forming cells (examples: Osteocel, OsteoAMP, PrimaGen).

Evidence noteAvailable studies are limited in quality and quantity; many products lack direct comparative trials to autograft, so clinical effectiveness versus autograft is uncertain.

Bioactive glass — definition and composition

TermBioactive glass

DefinitionA class of synthetic silica-based materials composed typically of SiO2, CaO, Na2O, and P2O5 that are used as bone graft substitutes and claimed to promote rapid hydroxyl carbonated apatite (HCA) formation and bone bonding.

Evidence noteDespite theoretical properties, there is insufficient high-quality evidence to conclude on clinical efficacy and safety compared with established graft materials.

Allograft (structural) — definition

TermAllograft (structural)

DefinitionStructural cortical or corticocancellous bone grafts (fresh-frozen or freeze-dried) used to provide mechanical support in spinal fusion reconstruction, and may be used with or without autograft.

Typical usesIndicated for anterior cervical reconstruction, posterior cervical fusion, thoracolumbar fusion, and interbody fusion scenarios per guideline framing.

rhBMP-2 — additional definition and clinical role

TermrhBMP-2

Clinical roleUsed as an adjunct or substitute to autograft in specific spinal fusion scenarios to promote fusion (e.g., ALIF, selected PLIF/TLIF, posterolateral fusion in high-risk patients) but has unique complication risks and indication constraints.

Safety considerationOff-label cervical application is associated with higher adverse event rates and FDA warnings; use should be limited to approved and guideline-supported scenarios.

Osseointegration — new definition

TermOsseointegration

DefinitionThe stable anchorage of an implant achieved by direct bone-to-implant contact.

RelevanceTerm added to policy definitions to clarify implant integration with host bone and documentation expectations.

Osteoconduction — new definition

TermOsteoconduction

DefinitionA process whereby bone grows on the surface of a scaffold or implant, providing a framework for new bone formation.

RelevanceAdded to policy definitions to describe scaffold-dependent bone growth properties of graft materials.

Osteoinduction — new definition

TermOsteoinduction

DefinitionThe process by which osteogenesis is induced through recruitment and stimulation of immature cells to develop into preosteoblasts, leading to new bone formation.

RelevanceIncluded in updated definitions to distinguish biologic activity of graft materials (e.g., BMPs, DBM).

Allograft / Autograft / Bone Marrow Aspiration — updated definitions

AllograftUpdated definition: transplant of tissue from one individual to another of the same species (allogeneic); see policy for exact wording.

AutograftUpdated definition: tissue grafted into a new position in the body of the same individual; ICBG remains gold standard for many fusions.

Bone Marrow Aspiration (BMA)Updated definition: removal of a small amount of bone marrow in liquid form for use in grafting or examination; definitions updated in policy to reflect current wording.

2025-12-01definitions_update

Added definitions for osseointegration, osteoconduction, and osteoinduction and updated definitions for allograft, autograft, and bone marrow aspiration.

2025-12-01supporting_information_update

Updated Clinical Evidence, FDA, and References sections to reflect the most current information and archived the previous policy version CS009NJ.R.